KYTX: Kyverna Therapeutics Growth-Adjusted Market Cap to Net Income

Brandmark of Kyverna Therapeutics (KYTX)

By outsourcing production and testing to third-party contractors, Kyverna Therapeutics (KYTX) maintains agility, which is further bolstered by the aggressive hiring of bioinformaticians and the use of stock options to retain R&D staff. The PEG ratio visualizes the outcome of this strategy, where the 0.00 level reflects the current market valuation. This approach strengthens the status of a promising brand developing breakthrough CAR-T therapies to combat autoimmune pathologies.

KYTX Kyverna: Price/Earnings to Growth Ratio in the range 02/21/2024 - 11/16/2026

Metric breakdowns and analytics for Kyverna (KYTX)

- share price and consensus valuation forecast:
General company analysis:KYTX - Kyverna Therapeutics, Inc
Signature product of Kyverna Therapeutics Inc.

To minimize risks when selecting high-growth assets, it is necessary to assess whether the market valuation is aligned with the pace of business expansion. This metric, calculated as the ratio of P/E to the annual growth rate of earnings per share, allows for the identification of undervaluation when the price-to-earnings-to-EPS growth ratio is below 1, which for Kyverna Therapeutics (KYTX) currently stands at 0.00, confirming capitalization potential driven by unique CAR-T therapy and inelastic demand for lupus treatment.

Competitors of Kyverna Therapeutics

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Holdings Inc. ENGN|PEG Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate Aclaris Therapeutics Inc.|TLSA: PEG Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (ventyxbio.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Theratechnologies Inc. THTX|Price/Earnings to Growth Multiple AVTX (avalotx.com)|Price/Earnings to Growth Multiple Eledon Pharmaceuticals, Inc. ELDN|Price/Earnings to Growth Ratio Agenus, Inc AGEN|Climb Bio Inc - Price/Earnings to Growth Ratio|Zura Bio Limited - PEG Multiple|Growth-Adjusted Market Cap to Net Income aTyr Pharma, Inc. ATYR|ADAG: PEG Multiple|Market Cap to Earnings and Growth Ratio IMA (ImageneBio)|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Connect Pharma (CNTB)|PEG Multiple Immunic Therapeutics (IMUX)|PEG Multiple ATRA (Atara Biotherapeutics)|Growth-Adjusted Payback Ratio IFRX|XFOR (X4 Pharma) - Price to Earnings Adjusted for Growth Rate|Growth-Adjusted Payback Ratio ACET (adicetbio.com)|CELU: PEG Multiple|inmunebio.com (INMB) - PEG Multiple|BRNS (Barinthus Biotherapeutics PLC) - PEG Multiple|KZR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Multiple|geovax.com - PEG Multiple|Growth-Adjusted Payback Ratio EDSA (Edesa Biotech Inc)|IBIO: PEG Multiple|Carisma Tx (CARM) - PEG Multiple|XTLB (XTL Biopharmaceuticals) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple HCWB (HCW Biologics, Inc.)|PEG Multiple Aptevo (APVO)|PEG Multiple AIM (aimimmuno.com)|PEG Multiple Aditxt Corp ADTX|GRI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple